Dexamethasone


Generic Medicine Info
Administration
Should be taken with food.
Contraindications
Systemic fungal infections; systemic infection unless being treated with specific anti-infectives. Perforation of drum membrane (otic). Administration of live virus vaccine.
Special Precautions
Patients with hypertension, acute MI, heart failure, diabetes mellitus, gastrointestinal diseases (e.g. diverticulitis intestinal anastomoses, active or latent peptic ulcer ulcerative colitis); ocular diseases (e.g. cataracts, glaucoma, history of ocular herpes simplex); osteoporosis, history of seizure disorder, thyroid disease. Renal and hepatic impairment. Elderly. Children. Pregnancy and lactation. Avoid abrupt withdrawal or rapid dose reduction. Ophth: This drug may cause blurring of vision, if affected, do not drive or operate machinery. Remove contact lenses prior to ophthalmic administration and reinsert after 15 minutes. Monitoring Parameters Monitor growth for children and intraocular pressure.
Adverse Reactions
Significant: Adrenal suppression (e.g. hypercortisolism, suppression of hypothalamic-pituitary-adrenal [HPA] axis); Kaposi sarcoma; myopathy; perineal irritation, psychiatric disturbance, immunosuppression (e.g. secondary infections, activation of latent infections, mask acute infection); increased intra-ocular pressure, open-angle glaucoma and cataracts. Rarely, anaphylactoid reactions. Endocrine disorders Growth retardation in children. Eye disorders: Bacterial keratitis, eye irritation and pruritus, burning sensation, ocular discomfort. General disorders and administration site conditions: Impaired wound healing. Investigations: Weight gain. Metabolism and nutrition disorders: Cushing's syndrome, obesity. Musculoskeletal and connective tissue disorders: Osteoporosis. Nervous system disorders: Headache, muscle atrophy. Psychiatric disorders: Euphoria, depression, suicidal tendencies. Skin and subcutaneous tissue disorders: Skin fragility.
Drug Interactions
Decreased plasma concentration with CYP3A4 inducers (e.g. barbiturates, carbamazepine, ephedrine, phenytoin, rifabutin, rifampicin). Increased plasma concentration with CYP3A4 inhibitors (e.g. erythromycin, ketoconazole, ritonavir). May increase renal clearance of salicylates. May enhances hypokalaemic effects of diuretics (acetazolamide, loop, thiazide), amphotericin B injection, corticosteroids, carbenoxolone, and K-depleting agents. May enhance anticoagulant effect of warfarin.
CIMS Class
Corticosteroid Hormones / Ear Corticosteroids / Eye Corticosteroids
ATC Classification
C05AA09 - dexamethasone ; Belongs to the class of products containing corticosteroids for topical use. Used in the treatment of hemorrhoids and anal fissures.
H02AB02 - dexamethasone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
D10AA03 - dexamethasone ; Belongs to the class of topical corticosteroids used in the treatment of acne.
S01BA01 - dexamethasone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye.
S02BA06 - dexamethasone ; Belongs to the class of corticosteroids used in the treatment of inflammation of the ear.
A01AC02 - dexamethasone ; Belongs to the class of local corticosteroid preparations. Used in the treatment of diseases of the mouth.
D07XB05 - dexamethasone ; Belongs to the class of moderately potent (group II) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
S03BA01 - dexamethasone ; Belongs to the class of corticosteroids used in ophthalmologic and otologic preparations.
D07AB19 - dexamethasone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
S01CB01 - dexamethasone ; Belongs to the class of corticosteroids/antiinfectives/mydriatics combinations. Used in the treatment of eye diseases.
R01AD03 - dexamethasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
Disclaimer: This information is independently developed by CIMS based on dexamethasone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in